Trial Profile
A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Elubrixin (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 17 Jun 2014 Results published in the Journal of Cystic Fibrosis.
- 16 Jun 2014 New trial record
- 16 Jun 2014 New trial record